Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Regulatory News: Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021. Jacques Th

2월 2일 19:10

Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality

Regulatory News: Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency

2020년 11월 26일 17:10

VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia i

2020년 11월 19일 17:47

Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency

Regulatory News: Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results w

2020년 11월 16일 09:22

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Regulatory News: Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed

2020년 11월 9일 15:39

VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the European Medicines Agency (EMA) accepted to review the Marketing Authorizat

2020년 11월 3일 16:09

Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injectio

2020년 10월 21일 11:48

Vifor Pharma announces outcome of AFFIRM-AHF topline data

Regulatory News: Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject® (intravenous ferric carboxymaltose) on heart failure hospitalizations and ca

2020년 9월 25일 17:43

Vifor Pharma Group Announces Successful Sale of OM Pharma

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:

2020년 9월 18일 16:02

Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee

Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory

2020년 9월 1일 16:37

Vifor Pharma Group Reports Continued Growth in H1 2020

Regulatory News: Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect C

2020년 8월 6일 15:02

VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six (46) patient phase-II dose-ranging trial in

2020년 5월 18일 17:36

92nd Vifor Pharma Group Annual General Meeting

Regulatory News: At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the current situation a

2020년 5월 15일 16:31

Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients

Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes progr

2020년 5월 6일 10:36

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance

Regulatory News: Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The c

2020년 3월 12일 15:35

Pioneering Project for Pharmaceutics - Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: · The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the U

2019년 5월 27일 10:53